VEGFA and hepatocellular carcinoma: A previous study by our team found that in patients with advanced HCC, there were no significant differences in survival or time to treatment discontinuation between immune checkpoint inhibitors or anti-vascular endothelial growth factor therapy following 1L atezolizumab + bevacizumab [29].